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ABSTRACT
Introduction: Alogliptin is an oral antihyper-
glycemic agent that is a selective inhibitor of
the enzyme dipeptidyl peptidase-4 (DPP-4),
approved for the treatment of type 2 diabetes
mellitus (T2DM). There currently exists no
comparative data to support the use of
alogliptin in combination with metformin
(met) and sulfonylurea (SU). A decision-focused
network meta-analysis (NMA) was performed to
compare the relative efficacy and safety of alo-
gliptin 25 mg once daily to other DPP-4 inhi-
bitors as part of a triple therapy regimen for
patients inadequately controlled on metformin
and SU dual therapy.
Methods: A systematic literature review was
conducted to identify published papers of ran-
domized controlled trials (RCTs) that compared
alogliptin with other DPP-4 inhibitors (li-
nagliptin, saxagliptin, sitagliptin, and vilda-
gliptin) at their Summary of Product
Characteristics (SmPC) recommended daily
doses, added on to metformin and SU. Com-
prehensive comparative analysis involving fre-
quentist meta-analysis and Bayesian NMA
compared alogliptin to each DPP-4 inhibitor
separately and collectively as a group.
Quasi-random effect models were introduced
when random effect models could not be
estimated.
Results: The review identified 2186 articles,
and 94 full-text articles were assessed for eligi-
bility. Eight RCTs contained appropriate data
for inclusion in the NMA. All analyses over all
trial population sets produced very similar
results, and show that alogliptin 25 mg is as
least as effective (as measured by change in
HbA1c from baseline, but supported by other
outcome measures: change in body weight and
FPG from baseline) and safe (as measured by
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incidence of hypoglycemia and adverse events
leading to study discontinuation) as all the
other DPP-4 inhibitors in triple therapy.
Conclusion: This decision-focused systematic
review and NMA demonstrated alogliptin 25 mg
daily to have similar efficacy and safety com-
pared to other DPP-4 inhibitors, for the treat-
ment of T2DM in adults inadequately
controlled on metformin and SU. (Funded by
Takeda Development Centre Americas; EXAM-
INE ClinicalTrials.gov number, NCT00968708).
Keywords: Alogliptin once daily; DPP-4
inhibitor; Network meta-analysis; Systematic
review; Triple therapy; Type 2 diabetes mellitus
INTRODUCTION
Patients with type 2 diabetes mellitus (T2DM)
often require multiple therapies to achieve gly-
cemic control. Combination therapy with a
dipeptidyl peptidase-4 (DPP-4) inhibitor and
metformin or sulfonylurea (i.e., dual therapy)
results in substantial and additive glucose-low-
ering effects in patients with T2DM. Alogliptin
(Vipidia) is the latest DPP-4 inhibitor to be
licensed in the UK and the fifth agent of its class
to be licensed. Alogliptin is licensed for the
treatment of T2DM in combination with other
glucose-lowering agents including insulin. The
safety and efficacy of alogliptin as monotherapy
and combination therapy in patients with
T2DM have been evaluated in numerous clini-
cal trials [1]. In a multicenter, randomized,
double-blind, placebo-controlled study, Nauck
et al. [2] assessed the efficacy of adding alo-
gliptin to metformin therapy in patients with
T2DM and inadequate glycemic control, for
26 weeks. The addition of alogliptin produced a
significantly greater decrease in HbA1c
(-0.60%) at the SmPC recommended dose of
25 mg once daily (qd) when compared to pla-
cebo (P\0.001). Rapid and significant fasting
plasma glucose (FPG) reduction from baseline
was also perceived as early as week 1 and con-
tinued through the length of trial to week 26 for
alogliptin 25 mg qd versus placebo [2]. Pratley
et al. [3] evaluated combination therapy of
alogliptin added to glyburide (a sulfonylurea,
SU) in 500 patients with T2DM inadequate
controlled on SU monotherapy and showed
significant HbA1c reductions of alogliptin
25 mg (-0.53%) compared with placebo
(?0.01%; P\0.001). Reductions were seen as
early as 4 weeks and continued through the
26-week period. More patients in the alogliptin
25 mg group achieved HbA1c reductions[0.5%
(26.3% with placebo and 50.5% with 25 mg of
alogliptin; P\0.001).
DPP-4 inhibitors also exert clinically relevant
glucose-lowering effects as oral triple therapy
with a good tolerability profile when added to
metformin plus SU as shown in randomized
clinical trials. Sitagliptin 100 mg once daily (qd)
significantly improved glycemic control and
b-cell function in patients with T2DM who had
inadequate glycemic control with glimepiride
plus metformin therapy [4]. Similarly adding
linagliptin 5 mg qd [5], vildagliptin 50 mg twice
daily (bid) [6], and saxagliptin 5 mg qd [7] to
metformin in combination with SU signifi-
cantly improved glycemic control in T2DM
patients and all were well tolerated. Adding
alogliptin 25 mg qd to a metformin–pioglita-
zone regimen provided superior glycemic con-
trol and potentially improved b-cell function
versus uptitrating pioglitazone in T2DM
patients, with no clinically important differ-
ences in safety [8].
There has been no study specifically evalu-
ating alogliptin in triple therapy when added to
metformin and SU. The EXAMINE trial was a
phase 3, multicenter, randomized, dou-
ble-blind, placebo-controlled study designed to
demonstrate non-inferiority of alogliptin versus
placebo with respect to a composite of major
adverse cardiac events (MACE) in high-risk
patients with T2DM. A total of 5380 patients
were randomized to either alogliptin (N = 2701)
or placebo (N = 2679) [9]. A substantial popu-
lation in EXAMINE entered on dual therapy
with metformin and SU with alogliptin or pla-
cebo added to this dual therapy (N = 1398;
alogliptin = 693, placebo = 705) and were fol-
lowed for up to 40 months (median 18 months)
[10]. A post hoc analysis of this subgroup data
has been performed [10].
For all patients on metformin ? SU at base-
line, characteristics were similar for the
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alogliptin and placebo groups (mean HbA1c,
8.14%). By the end of the study period, the least
square (LS) mean difference for change from
baseline of HbA1c was -0.52% (P\0.001) [10].
The alogliptin and placebo groups did not differ
in the percentage of patients with at least one
adverse event (75.2% alogliptin and 79.6% pla-
cebo) or serious adverse events (28.3% aloglip-
tin and 32.1% placebo). There was no
significant difference in the incidence of any
report of hypoglycemia (8.8% alogliptin and
6.7% placebo, P = 0.161) or serious hypo-
glycemia (1.30% alogliptin and 0.43% placebo,
P = 0.088) [10]. These data demonstrate that
triple therapy with alogliptin, metformin, and
SU was effective and well tolerated.
Head-to-head comparisons between the
DPP-4 inhibitors are uncommon, and only one
trial comparing the efficacy of saxagliptin 5 mg
qd and sitagliptin 100 mg qd added to met-
formin in T2DM patients (i.e., dual therapy) has
been published to date and demonstrated
non-inferiority in the primary efficacy endpoint
of change in HbA1c from baseline. The safety
profile was similar for the two DPP-4 inhibitors,
with modest weight loss and almost no increase
in the incidence of reported or documented
hypoglycemic episodes [11]. There currently
exists no comparative trial evidence assessing
the relative efficacy and safety of alogliptin as a
third-line treatment option added to dual ther-
apy with metformin and SU. Several network
meta-analyses (NMA) have been performed of
different classes of drug treatment for T2DM in
triple therapy (following failure with met-
formin ? SU) including DPP-4 inhibitors,
although none have compared the relative
efficacy of each DPP-4 treatment or included
alogliptin within the DPP-4 inhibitor class
[12–15]. This is because of a previous lack of
available published triple therapy data for alo-
gliptin. However, the recent availability of new
triple therapy subgroup analysis of the aloglip-
tin EXAMINE trial has enabled an NMA of the
relative efficacy and safety of alogliptin versus
comparator DPP-4 inhibitors added to met-
formin and SU to be performed.
Hence, the objective of this study was to
perform a systematic review and NMA using
Bayesian methods of the relative efficacy and
safety of alogliptin 25 mg qd added to met-
formin and SU dual therapy, compared to other
DPP-4 inhibitors added to metformin and SU
dual therapy. The analysis has been performed
using a clinical decision-focused approach and
so covers those individual comparators that are
most likely to be displaced by the introduction
of a new DPP-4 agent, alogliptin, for use in tri-
ple therapy, which are the current alternative
DPP-4 inhibitors used in clinical practice in the
UK (i.e., linagliptin, saxagliptin, sitagliptin, and
vildagliptin), rather than including other classes
of anti-T2DM therapies less likely to be dis-
placed by alogliptin in clinical practice such as
GLP-1, SGLT-2, or TZD agents. From a methods
perspective this approach minimizes noise and
heterogeneity in the network by focusing on
the comparator evidence of direct relevance to
clinical decision-making in a UK context.
METHODS
This article is based on previously conducted
studies and does not involve any new studies of
human or animal subjects performed by any
authors.
Systemic Literature Search: Identification
of Trials
A systemic literature review (SLR) was con-
ducted relevant to a UK clinical and Health
Technology Assessment Database (HTA) deci-
sion-making context for assessing the relative
efficacy and safety of alogliptin versus other
DPP-4 inhibitors in combination with met-
formin and sulfonylurea. Hence, the SLR cov-
ered triple therapy studies for alogliptin and
other DPP-4 inhibitors (linagliptin, saxagliptin,
sitagliptin, and vildagliptin), used in triple
therapy (i.e., in combination with metformin
and sulfonylurea) in the treatment of patients
with T2DM in UK clinical practice. The SLR was
conducted in accordance with guidance rec-
ommended by the National Institute of Health
and Care Excellence (NICE) [16] as well as the
methodological principles recommended by the
University of York Centre for Reviews and Dis-
semination [17], and is reported according to
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the Preferred Reporting Items for Systematic
Review and Meta-Analyses (PRISMA) [18].
MEDLINE, EMBASE, Medline-In-Process, and
other non-indexed citations (including PubMed
records), Cochrane Central Register of Con-
trolled Trials, Cochrane Database of Systematic
Reviews (CDSR), Database of Abstracts of
Reviews of Effectiveness (DARE), HTA, and ISI
Web of Science-Proceedings. In addition, bibli-
ographies of reviews, retrieved articles, key
conference abstracts, and other relevant sources
(e.g., ClinicalTrials.gov, EU Clinical Trials
Register) were searched for other studies. The
full search strategies are available in the sup-
plementary material (Tables S1.1–S1.4). All
electronic databases were searched between 29
and 31 January 2016. All searches were limited
to English-language publications. The EXAM-
INE triple therapy subgroup analysis data [10]
was identified and provided by Takeda as the
abstract had been accepted to be presented at
the American Diabetes Association (ADA) in
New Orleans, LA, USA from10 to 14 June 2016.
The search strategy was built around the
PICOS framework (Population, Interventions,
Comparators, Outcomes, and Study designs).
The PICOS framework allows for all possible
combinations of search terms. Key inclusion
criteria were as follows: RCTs reporting adult
patients (C18 years) with T2DM treated with
alogliptin ?metformin ? SU or a DPP-4 ?met-
formin ? SU triple therapy only; RCTs reporting
one or more of the following outcomes: mean
change from baseline in HbA1c, FPG, body
weight, BMI, the occurrence of at least one
hypoglycemic event, and treatment discontin-
uation due to any adverse event; RCTs that
contained the SmPC recommended daily dose
of alogliptin and the other DPP-4 inhibitors of
interest: alogliptin 25 mg qd, saxagliptin and
linagliptin 5 mg qd, sitagliptin 100 mg qd, and
vildagliptin 50 mg bid; RCTs that include com-
parisons between the DPP-4 agents of interest
and placebo ?metformin ? SU, or form head-
to-head trials versus other DPP-4 agents. Out-
comes were to be reported at 24 ± 6 weeks. This
time period was sufficiently long to include all
studies that reported outcomes at 24 weeks, as
well as the alogliptin EXAMINE study which
reported efficacy assessment at 6 months
(26 weeks) [10].
The study selection consisted of two stages: a
first-pass screening of titles and abstracts
according to the PICOS criteria, followed by a
second-pass screening of full-text articles
according to the inclusion criteria for consid-
eration in the NMA. Both stages were conducted
by two reviewers with a third reviewer checking
the selection of full-text articles. Any disagree-
ments regarding the inclusion/exclusion of
articles were discussed until a consensus was
reached. Full-text articles were obtained, and
the reference lists of these studies and system-
atic reviews were also hand searched to check
and identify any further publications likely to
be of relevance. The study selection process was
documented detailing reasons for inclusion and
exclusion for consideration in the NMA. Data
extraction was performed by one reviewer and
verification by a second. The relevance of each
study was assessed according to the inclusion/
exclusion criteria set out previously in the sys-
tematic literature review protocol. Study quality
was assessed using a question checklist adapted
from that used in the NICE Single Technology
Appraisal specifications checklist for manufac-
turer/sponsor submission of evidence for
assessing the internal validity and the quality of
reporting in the published RCT study (see
Table S2 in the supplementary material) [19].
Outcome Measures
The primary efficacy outcome considered was
HbA1c change from baseline. In addition, body
weight change from baseline and change in
fasting plasma glucose (FPG) from baseline were
included, along with two safety outcomes:
incidence of hypoglycemia, and discontinua-
tions due to adverse events. According to rec-
ommendations from the American Diabetes
Association (ADA), World Health Organization
(WHO), and American College of Endocrinolo-
gists (ACE), HbA1c level is considered the ‘‘gold
standard’’ in assessment of metabolic control
and the specific level of HbA1c constitutes the
target at which treatment of both type 1 and 2
diabetes mellitus should be aimed [20]. All three
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organizations also underline the importance of
normalizing FPG, and the relationship this
endpoint has with HbA1c to improve glycemic
control. In addition, the relationship between
weight loss and glycemic improvement has
been seen in several observational studies as
well [21–23].
Mean values and associated measures of
variability [standard deviation (SD), standard
error (SE), confidence intervals (CIs), and P val-
ues] were extracted for all endpoints. Where
studies did not explicitly report standard errors
for continuous endpoints these were imputed
according to the recommendations detailed in
the Cochrane handbook for systematic reviews
of interventions [24]. Within the study by
Lukashevich et al. [6], an image depicting the
adjusted mean change (and s.e.) of HbA1c for
the trial treatments and their difference was
scanned. This was then inputted into the soft-
ware package Engauge Digitizer V6.2 which
extracted the standard errors (prudent as the
only available information related to effect




A Bayesian NMA combining both indirect and
direct evidence synthesis was conducted to
enable individual pairwise treatment compar-
isons between the DPP-4 inhibitors. The Baye-
sian framework used Markov Chain Monte
Carlo (MCMC) methods implementing the
guidelines laid down in the Evidence Synthesis
Technical Support Document Series produced
by the NICE Decision Support Unit [25–28].
For each outcome, the protocol-driven
intention was that both fixed and random
effects models were to be run with model
goodness of fit statistics used to choose between
them. However random effects models require
trials that repeat pairwise comparisons. For the
main analysis set only two trials repeated the
same comparison (involving sitagliptin versus
placebo). Hence, there was insufficient data to
estimate the between-study contrast variance
within the random effects model. Therefore,
fixed effects modelling was used for pairwise
comparisons, and random effects modelling was
also used for comparisons between alogliptin
and the comparator DPP-4 inhibitors grouped as
a category. In order to retain the advantages of
random effects modelling for pairwise compar-
isons (including alogliptin vs. each comparator
DPP-4 inhibitor), a ‘‘quasi-random’’ effects
modelling approach was used, based on inputs
from the grouped DPP-4 inhibitor comparisons
(utilizing five different prior distributions).
The various implications of the different
models attempted on the perceived efficacy of
alogliptin versus other DPP-4 inhibitors could
then be assessed. If there was a qualitative dif-
ference in this perceived efficacy between dif-
ferent models, then deviance information
criteria (DIC) could be used to judge amongst
them. Lower DIC scores indicate better fit with
differences greater than 5 points providing
confidence that the difference could not be due
to chance [29]. Total residual deviance was also
calculated: a high total residual deviance rela-
tive to data points (total number of trial arms)
indicates poor fit. Such a measure is an impor-
tant adjunct to DIC which can only make
comparisons between models.
In addition to the Bayesian analyses, fixed
and random effect frequentist meta-analysis
models were undertaken grouping all DPP-4
inhibitors (including alogliptin) against placebo
(both sets in combination with
metformin ? SU).
The base case (main analysis set) involved all
the studies where data was presented for the full
analysis set (FAS)/intention to treat (ITT) set,
thereby excluding PP studies and studies where
it was unclear which data set was presented.
Within the Bayesian NMAs treatment effects
were assessed as follows: for continuous vari-
ables, analysis was performed on the estimated
difference between treatments in mean change
from baseline to study end, together with 95%
confidence/credible intervals. For dichotomous
variables, analysis was performed on treatment
log odds ratio, together with 95% confi-
dence/credible intervals. In addition, the prob-
ability that alogliptin was non-inferior to
grouped DPP-4 inhibitors (difference in treat-
ment contrast between alogliptin and
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comparator less than 0.3% HbA1c in the com-
parator favor) was derived on the basis of a
difference of 0.3% in HbA1c change from
baseline considered as a clinically meaningful
difference [30].
Heterogeneity between trials was assessed in
both frequentist and Bayesian paradigms.
Within the frequentist meta-analysis, the value
associated with the Q test, the between-trial
variance of the treatment effect under random
effects, and the I-squared statistics were all cal-
culated. I-squared provides an estimate of the
percentage of variability in effect estimates that
are due to heterogeneity rather than sampling
error, and the values from this were interpreted
according to the Cochrane Handbook [24]. An
I-squared below 40% ‘‘might not be important’’
whilst 50% to 90% ‘‘may represent substantial
heterogeneity’’ [24]. These results are displayed
within the frequentist forest plots.
From the Bayesian analysis, leverage plots
were used to identify any specific trials that
appear as outliers (in terms of being either
influential or poorly fitted). Trials that are
heterogeneous in terms of key parameters are
likely to be either influential or poorly fitted
and hence will stand out on such a plot.
Inconsistency checks were also carried out
where necessary.
NMA Sensitivity Analyses
Sensitivity analysis was conducted on the pri-
mary endpoint, change in HbA1c from baseline,
for the main population analysis set involving:
addition of non-FAS (ITT) studies, i.e., PP stud-
ies, and studies where it was unclear which data
set was presented; removal of studies with
baseline HbA1c values that potentially differed
from the rest; exclusion of alogliptin compara-
tor DPP-4 studies defined as moderate or poor
quality.
Within the main analysis set, sensitivity to
trial heterogeneity was performed by examining
the effect on results of removing trials identified
as outliers on the leverage plots.
NMA covariate regression techniques were
also implemented, examining sensitivity to
between-trial differences in age and gender for
the endpoints of change in HbA1c, change in
body weight, and the incidence of hypo-
glycemic episodes. In addition, baseline HbA1c
and baseline body weight were also examined as
covariates in the HbA1c and body weight anal-
yses, respectively.
All the above sensitivity analyses were pre-
specified in the NMA protocol. However, a post
hoc HbA1c sensitivity analysis was attempted
using the hierarchical ‘‘partial pooling’’ method
that may obviate the need to perform formal
multiple testing correction procedures such as
Bonferroni [31]. This method was applied to
one sensitivity analysis that previously pro-
duced a statistically significant (uncorrected)
difference using a Bayesian fixed effect individ-
ual treatment NMA.
More in-depth discussion of the statistical
methodology is presented in the technical
appendix of the supplementary material.
RESULTS
Systematic Review Results
The systematic literature search identified a
total of 2186 hits before duplication. After
deduplication and abstract screening, 94 full-
text articles were assessed for eligibility in the
NMA. To reduce heterogeneity among the RCTs
identified in the systematic review and to
improve generalizability of the NMA estimates,
additional criteria were defined for inclusion of
studies in the NMA. Six studies were initially
selected for inclusion into the NMA from the
systematic search [4–7, 10, 32]. In addition to
these six studies, an abstract in support of the
efficacy and safety of alogliptin evaluating sub-
jects treated with only metformin and SU at
baseline from the EXAMINE trial [10] was pro-
vided by Takeda, along with a non-indexed
study identified from ClinicalTrials.gov (Iden-
tifier: NCT01590771) [33], taking the total
amount of studies to eight. A PRISMA flow
diagram summarizing search results and study
selection is provided in the supplementary
material (Fig. S1). TableS3 in the supplementary
material presents study and patient character-
istics from the eight RCTs included in the NMA.
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The patient characteristics were generally
similar across the eight studies: the average age
ranged from 55.0 to 62.9 years; the proportion
of male patients ranged from 45.0% to 70.9%
and, where reported, the average duration of
T2DM ranged from 7.0 to 13.3 years. Baseline
HbA1c ranged from 8.15% to 8.80% across
treatment arms in the studies. In terms of other
characteristics, the majority of patients were
Caucasian in each study apart from Chen et al.
[34] and NCT01590771 [33] where the patients
were Chinese, and Hong et al. [32] (Clini-
calTrial.gov: NCT01099137) where the patients
were Korean. All patients were reported to be
uncontrolled on metformin ? SU dual therapy
in line with inclusion criteria for the systematic
review and NMA. Where reported, there were
some differences in the type of SU given and
their dose (glimepiride or gliclazide); the dose of
metformin; and duration of prior metformin or
SU. However, it is unlikely that the variation
observed has a significant bias on the efficacy
and safety outcomes across studies. Study
design was similar in all of the eight studies
included in the NMA. The treatment duration
was 24 weeks (26 weeks for the alogliptin
EXAMINE study), and the majority were pla-
cebo controlled. All studies were in the patient
population of interest; T2DM patients with
inadequate glycemic control despite treatment
with metformin ? SU dual therapy. The end-
point data for the individual trials included in
the NMA is presented in the supplementary
material: Table S4 (HbA1c), Table S5 (body
weight), Table S6 (FPG), Table S7 (hypo-
glycemia), and Table S8 (discontinuation due to
adverse events).
Network Meta-Analysis Results
HbA1c Change from Baseline: Base Case
Analysis
The base case analysis for HbA1c change from
baseline was performed on the FAS/ITT data for
six of the eight studies (EXAMINE, Heller et al.
[10], Hermansen et al. [4], Lukashevich et al. [6],
Moses et al. [7], NCT01590771 [33], and Owens
et al. [5], ClinicalTrials.gov NCT00602472). The
relevant network plot is shown in Fig. 1. The
two studies excluded from the main analysis
group were the studies where analysis was car-
ried out per protocol (Chen et al. [34] and Hong
[32]), but were included within a sensitivity
analysis. From the quality assessment of each
study for the primary outcome, the same two
studies were classed as of poor quality as well.
The forest plot in Fig. 2 shows the mean
change in HbA1c (%) recorded in the main
analysis set [4–7, 10, 32, 34]. The mean differ-
ence (MD) for each DPP-4 inhibitor against
placebo is shown on the right and also plotted.
With a mean difference against placebo of
-0.62% (95% CI of -0.76 to -0.48%) alogliptin
falls in the middle of the spread of the indi-
vidual trial results with means ranging from
-0.41 to -0.89%. The two trials that provide
these range endpoints both refer to the same
treatment (sitagliptin) against placebo [4, 33].
All Bayesian models converged without
problems. For the primary analysis, Fig. 3 pre-
sents a forest plot of all possible pairwise con-
trast comparisons between the individual DPP-4
treatments under both the fixed and quasi-ran-
dom effect models. For the comparisons
involving alogliptin, none approached statisti-
cal significance and all point estimates were
within 0.15% HbA1c of zero difference (three of
the four within 0.05%). Statistically insignifi-
cant differences were also recorded for all other
DPP-4 comparisons. The grouped DPP-4
Fig. 1 HbA1c (%) change from baseline: main analysis
set—network plot
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analysis against alogliptin under various fixed
and random effect models produced the com-
parison results shown in Fig. 4—all model defi-
nitions produced contrasts that also show
non-inferiority (all estimates around 0.04 Hba1c
% in absolute value). The posterior estimates of
the between-trial standard deviations from
these random effect models were in close
agreement with medians at or close to 0.17 (see
Fig. S2 in the supplementary material). Hence
this value was inputted into the individual
DPP-4 treatment quasi-random effect model.
Fig. 2 HbA1c (%) change from baseline: main analysis
set—forest plot of frequentist meta-analysis showing
individual trial results and grouped DPP-4 treatments
against placebo ﬁxed and random effect models (all with
metformin ? SU). MD mean difference
Fig. 3 HbA1c (%) change from baseline: main analysis set ﬁxed and quasi-random (between-trial SD ﬁxed at 0.17) effects
models forest plot—pairwise differences between DPP-4 treatments (with metformin ? SU)
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The mean estimates from this model were very
similar to the fixed effect mean results as shown
in Fig. 3, but with an approximate doubling of
the confidence interval ranges.
The non-inferiority probabilities for aloglip-
tin against individual comparator DPP-4 treat-
ments are shown in Table 1. Indeed, the
probability of alogliptin being non-inferior to at
least one individual DPP-4 treatment is 1 under
the fixed effects model and 0.98 under the
quasi-random effects model. Grouping the
comparator DPP-4 inhibitors shows similar
results for the non-inferiority of alogliptin
HbA1c efficacy (Table 2).
Model fit and heterogeneity assessments that
that the quasi-random effects model
(DIC = 24.2) is superior to the fixed effects
model (DIC = 31.9). The poor fit of the fixed
effect model is displayed in the Leverage plot
shown in Fig. 5 [27]. The circles in this
Fig. 4 HbA1c (%) change from baseline: main analysis set forest plot—mean differences between alogliptin and other
grouped DPP-4 treatments (with metformin ? SU) under various random and ﬁxed effects models
Table 1 HbA1c change from baseline: main analysis set—non-inferiority (\0.3% in competitor’s favor) of alogliptin 25 mg
under ﬁxed effects and quasi-random effects models (all regimens with metformin ? SU)
Comparators Non-inferiority probability of alogliptin 25 mg
Fixed effects model Quasi-random effects model (SD 5 0.17)
Saxagliptin 5 mg 0.9833 0.8325
Sitagliptin 100 mg 0.9947 0.8757
Vildagliptin 100 mg 0.8713 0.7173
Linagliptin 5 mg 0.9995 0.8779
At least one 1.0000 0.9773
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figure that lie well outside the red parabola
(considered outliers) are the trial arms in the
two studies involving sitagliptin [4, 33]. On the
equivalent figure drawn for the quasi-random
effects model (Figure S3 supplementary mate-
rial) these arms fall well within this parabola.
Table 2 HbA1c change from baseline: main analysis set—non-inferiority (\0.3% in competitor’s favor) of alogliptin 25 mg
against remaining DPP-4 inhibitors grouped under various ﬁxed and random effect models (with goodness of ﬁt statistics)
Models run Non-inferiority probability
of alogliptin 25 mg
DIC Residual deviance
Fixed effects (SD = 0) 0.9995 27 19
SD Prior* Uniform (0, 0.5) 0.8837 24.12 12.77
SD Prior* Uniform (0, 1) 0.8716 24.18 12.73
SD Prior* Uniform (0, 2) 0.8687 24.2 12.73
SD Prior* HalfCauchy (0.2) 0.9168 24.35 13.29
SD Prior* HalfCauchy (0.5) 0.8877 24.16 12.86
Each row represents a different Bayesian model distinguished by the prior distribution for the between-trial standard
deviation shown in the left most column
DIC deviance information criteria
Fig. 5 HbA1c change from baseline: main analysis set
(ﬁxed effects model)—leverage versus deviance residual
plot incorporating model ﬁt statistics. Values that lie
outside the drawn smooth parabola with a constant of 3
(the red curves) can generally be identiﬁed as contributing
to the model’s poor ﬁt
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Frequentist meta-analysis (combining the
DPP-4 treatments and contrasting against pla-
cebo) supports the Bayesian findings as shown
by the bottom rows of Fig. 2: alogliptin falls well
within the middle of the confidence ranges
produced by these fixed and random effect
models and heterogeneity problems are indi-
cated by the I-squared of 55%.
HbA1c Change from Baseline: Sensitivity
Analysis
To explore the impact of study heterogeneity,
all analyses were repeated eliminating the two
sitagliptin trials (Hermansen et al. [4] and
NCT01590771 [33]). As both these studies were
the only alogliptin comparator DPP-4 treatment
studies that were deemed to be of moderate
quality, this trial set also serves as sensitivity
analysis relating to study quality.
The elimination of the two studies had no
qualitative impact: individual treatment results
under the Bayesian fixed effect NMA remained
the same as displayed in Fig. 3 (omitting the
comparisons involving sitagliptin) and the
non-inferiority probabilities of alogliptin
against individual DPP-4 treatments remained
high (increasing for the quasi-random effects
models where the between-trial standard devi-
ation fell to 0.1). For alogliptin versus other
DPP-4 inhibitors grouped comparisons, the
non-inferiority probabilities remain high: 0.999
probability that alogliptin is non-inferior to
other DPP-4 inhibitors based on the fixed effects
model (Table 3). In addition, the goodness of fit
statistics for the fixed effects model were the
best (although not decisively).
All other sensitivity analysis results involv-
ing adding or removing trials produced the
same strong qualitative assessment for the
change in HbA1c endpoint: the results indicate
no difference between the DPP-4 inhibitors.
These results are presented in the supplemen-
tary material (Figs. S4–S16, Tables S9–S14), with
the exception of the sensitivity analysis
removing studies with potential outlier baseline
HbA1c values (shown below).
From the leverage plot analysis potential
outlier trials that were identified were Luka-
shevich et al. [6] and NCT01590771 [33] which
had relatively high baseline HbA1c values of
8.75% and 8.61%, respectively, contrasting with
the other studies in the main analysis set (range
8.15% to 8.37%). Under the fixed effects model
only, this resulted in a marginal statistically
significant advantage for sitagliptin over alo-
gliptin decreasing HbA1c by an additional
0.27% (95% CIs of 0.02% to 0.52%). Figure 6
which displays all the fixed effect contrasts in
dark blue. The ‘‘partial pooling’’ estimates in
yellow, which perform a moderate adjustment
for multiple testing considerations [31], elimi-
nate this statistical difference. This insignifi-
cance viewpoint is reinforced by the
quasi-random effects estimates shown in green
which do not attempt to adjust for multiple
testing considerations but allow for between-
trial variability in treatment effects. Goodness
of fit statistics for these various models have no
power to differentiate between them, as there
are insufficient trials and each treatment con-
trast comparison occurs only once. However,
grouping the DPP-4 inhibitors suggests that
between-trial variability should be allowed for
(worst DIC and significantly worst residual
deviance observed for the fixed effects model).
All comparisons between grouped DPP-4 inhi-
bitors and alogliptin were highly insignificant.
Non-inferiority results and the goodness of fit
statistics are presented in Table 4 for the
grouped comparison.
The meta regressions examining the sensi-
tivity of HbA1c treatment efficacy to baseline
Hba1c, age, and male/female ratio disparities
also produced statistically insignificant results.
Table 5 presents the results for baseline HbA1c
and indicates that the sensitivity analysis that
eliminated the two higher baseline Hba1c trials
was inappropriate. Results for the other covari-
ates are shown in Tables S15–S17 in the sup-
plementary material.
Even more evidence is presented in the sup-
plementary material to support the claim that
alogliptin is equivalent to other DPP-4 treat-
ments in terms of HbA1c change from baseline.
This is based around the p value of the
meta-analysis Q statistic and the nature of the
study network (see technical appendix for
methodological explanation and text below
Fig. S4 for results/interpretation). Figure S17 of
the supplement contains a forest plot of
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vildagliptin 100 mg versus all other DPP-4 inhi-
bitors grouped. Vildagliptin achieved the best
point estimate based on this outcomemeasure so
that it is reassuring that this figure shows that
differences are statistically insignificant under all
model scenarios examined.
Table 3 HbA1c change from baseline: main analysis set removing two outlier studies—non-inferiority of alogliptin 25 mg
against remaining DPP-4 inhibitors grouped under various ﬁxed and random effects models (with goodness of ﬁt statistics)
Models run Non-inferiority probability
of alogliptin 25 mg
DIC Residual deviance
Fixed effects (SD = 0) 0.9994 13.09 7.09
SD Prior* Uniform (0, 0.5) 0.9152 14.47 7.38
SD Prior* Uniform (0, 1) 0.8914 14.62 7.43
SD Prior* Uniform (0, 2) 0.8784 14.69 7.46
SD Prior* HalfCauchy (0.2) 0.9463 14.16 7.29
SD Prior* HalfCauchy (0.5) 0.9146 14.45 7.38
Each row represents a different Bayesian model distinguished by the prior distribution for the between-trial standard
deviation shown in the left most column
DIC deviance information criteria
Fig. 6 HbA1c (%) change from baseline: main analysis set
excluding two outlier studies with higher baseline HbA1c
values—pairwise differences between DPP-4 treatments
(with metformin ? SU) under ﬁxed, partial pooling, and
quasi-random effects (SD = 0.2) model assumptions
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Body Weight Change from Baseline
From frequentist analysis alogliptin (based on
data from the EXAMINE trial) [10] was associ-
ated with the least mean body weight gain
compared to placebo of all the DPP-4 inhibitors
(0.14 kg over 26 weeks), as shown in the forest
plot of Fig. 7. This resulted in favorable NMA
pairwise DPP-4 inhibitor comparisons as shown
in Fig. 8. Two of these comparisons (against
saxagliptin and sitagliptin) are bordering on
statistical significance in the fixed effects rep-
resentation. However, the range of the 95%
confidence intervals across all the pairwise
comparisons together with the quasi-random
effects results suggest that in reality this
apparent advantage is likely to be spurious. This
is reinforced by grouping the non-alogliptin
DPP-4 inhibitors and comparing against it—re-
sults under all NMA fixed and random effect
models produced point estimates in alogliptin’s
favor but with zero overlapping confidence
intervals. Further diagnostic figures related to
weight change are provided in Figs. S18–S21 of
the supplementary material.
Bayesian covariate regression analysis for
gender, age, and baseline body weight indicated
that none of these covariates had any explana-
tory power (all 95% confidence intervals widely
overlap zero) and the models that excluded any
covariates had better DIC scores than corre-
sponding models that included them
Table 4 HbA1c change from baseline: main analysis set excluding two outlier studies with higher baseline HbA1c values—
non-inferiority of alogliptin 25 mg against remaining DPP-4 inhibitors grouped under various ﬁxed and random effects
models (with goodness of ﬁt statistics)
Models run Non-inferiority probability
of alogliptin 25 mg
DIC Residual deviance
Fixed effects (SD = 0) 0.9981 16.98 10.98
SD Prior* Uniform (0, 0.5) 0.8327 16.06 8.31
SD Prior* Uniform (0, 1) 0.7966 16.07 8.23
SD Prior* Uniform (0, 2) 0.7791 16.12 8.23
SD Prior* HalfCauchy (0.2) 0.8774 16.12 8.54
SD Prior* HalfCauchy (0.5) 0.8276 16.09 8.33
Each row represents a different Bayesian model distinguished by the prior distribution for the between-trial standard
deviation shown in the left most column
DIC deviance information criteria
Table 5 Baseline HbA1c covariate: coefﬁcient details and goodness of ﬁt statistics—main analysis set (alogliptin trial
omitted) other DPP-4 treatments grouped
Models run Coefﬁcient Lower 95% CI Upper 95% CI DIC Residual deviance
Fixed effects 0.0309 -0.3439 0.4056 24.97 17.97
Quasi-random SD = 0.05 0.0473 -0.3806 0.4752 22.57 14.94
Quasi-random SD = 0.1 0.0638 -0.4852 0.6137 20.15 11.62
Quasi-random SD = 0.2 0.0705 -0.7959 0.9381 19.36 9.96
Each row represents a different Bayesian model distinguished by the prior distribution for the between-trial standard
deviation shown in the left most column
DIC deviance information criteria
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(Tables S18–21 in the supplementary material).
This supports a finding of comparability
between alogliptin and the DPP-4 inhibitors,
and between the DPP-4 inhibitors, with regards
to change in body weight.
Incidence of Hypoglycemic Events
The individual trial results for the number of
hypoglycemic events in Fig. 9 show that alo-
gliptin achieves a relatively low risk ratio
against placebo (point estimate of 1.54, almost
Fig. 7 Body weight (kg) change from baseline: forest plot of frequentist meta-analysis showing individual trial results and
grouped DPP-4 treatments against placebo ﬁxed and random effects models (all with metformin ? SU)
Fig. 8 Body weight (kg) change from baseline: main analysis set—ﬁxed and quasi-random (between-trial SD ﬁxed at
0.25 kg) effects models forest plot. Pairwise differences between DPP-4 treatments (with metformin ? SU)
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joint best with linagliptin) compared to other
DPP-4 inhibitors. This is reflected in the Baye-
sian DPP-4 individual treatment NMA compar-
ison results shown in Fig. 10. For the fixed effect
model, this comparison against sitagliptin is
statistically significant. Again though, this is
likely to be spurious—the quasi-random effects
model fitted significantly better (DIC more than
5 better) which produced overlapping zero
confidence intervals for contrasts (as did all
Fig. 9 Incidence of hypoglycemic events: forest plot of frequentist meta-analysis showing individual trial results and
grouped DPP-4 treatments against placebo, ﬁxed and random effect models (all with metformin ? SU)
Fig. 10 Incidence of hypoglycemic events: main analysis set; ﬁxed and quasi-random (between-trial SD ﬁxed at 1) effects
models forest plot. Pairwise comparisons between DPP-4 treatments (with metformin ? SU) measured by log odds ratios
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alogliptin versus other DPP-4 inhibitor grouped
NMA analyses). The results for the number of
hypoglycemic events do not appear to be sen-
sitive to covariates, age or gender. These pre-
dictors had no explanatory power in the
covariate regression equations (all 95% CIs
overlap zero) and DIC scores all slightly
improve on their removal. Thus, comparable
outcomes for alogliptin versus other DPP-4
inhibitors and between DPP-4 inhibitors for the
incidence of hypoglycemic events are supported
by the analyses.
Adverse Events Leading to Study
Discontinuation
The trial results used in the analysis of adverse
events leading to study discontinuation are
shown in Fig. 11. The results from this forest
plot support that alogliptin has a similar safety
profile to the other DPP-4 inhibitors when
compared against placebo. This is supported by
all Bayesian NMA analyses with all contrasts
having confidence intervals crossing zero. The
results for pairwise DPP-4 inhibitor comparisons
are shown in Fig. 12.
DISCUSSION
The current NICE guidelines (NG28) for the
management of T2DM in adults recommend:
‘‘triple therapy with metformin, a DPP-4 inhi-
bitor and a sulfonylurea as an option if dual
therapy with metformin and another oral drug
(including SU) has not continued to control
HbA1c to below the person’s individually
agreed threshold’’ [35]. There is no comparative
data on the efficacy and safety of alogliptin
against other DPP-4 inhibitors in triple therapy
added to metformin and sulfonylurea, and until
recently no data was available to investigate the
clinical effectiveness of alogliptin in a triple
therapy context having previously received
metformin and sulfonylurea alone. However,
data has now become available for alogliptin in
this patient population from a large subgroup of
the EXAMINE study [10]. The EXAMINE study
provides efficacy and safety evidence for alo-
gliptin triple therapy against dual therapy with
metformin and sulfonylurea. Using data from
the EXAMINE subgroup, the current study
reported in this paper presents the methods and
results of a decision-focused SLR and NMA to
investigate the relative efficacy and safety of
alogliptin 25 mg in triple therapy compared
with the other DPP-4 inhibitors currently used
in UK clinical practice.
The NMA of DPP-4 inhibitors within triple
therapy (with metformin ? SU) has indicated
that there is no evidence of a difference for
alogliptin compared to other DPP-4 inhibitors
(sitagliptin, saxagliptin, vildagliptin, and
Fig. 11 Adverse events leading to study discontinuation: forest plot of frequentist meta-analysis showing individual trial
results and grouped DPP-4 treatments against placebo, ﬁxed and random effects models (all with metformin ? SU)
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linagliptin) in terms of key efficacy and safety
outcomes: HbA1c mean change from baseline,
mean change in body weight from baseline,
number of patients experiencing hypoglycemic
events, and number of patients experiencing
adverse events leading to study discontinua-
tion. This similarity of the efficacy and safety of
the DPP-4 inhibitors used in triple therapy has
been established by multiple complementary
analysis methods including simple frequentist
forest plots, Bayesian NMA analysis at the
individual DPP-4 treatment level, and Bayesian
NMA analysis of alogliptin versus all other
DPP-4 inhibitors grouped. A range of sensitivity
analyses and meta regression covariate adjust-
ment techniques for the primary outcome of
HbA1c change from baseline are also all sup-
portive of a finding of comparable efficacy. A
simple non-technical illustration of this is pro-
vided in Fig. 2 which shows that shows that the
EXAMINE trial [10] falls in the middle when
visually comparing the confidence (error) bars
for each of the six trials included (all compar-
isons against placebo), and that the greatest
difference in the results involves the same
treatment, sitagliptin. Therefore, any differ-
ences between DPP-4 treatments in terms of
HbA1c efficacy appear less than the variability
within the same treatment comparison between
separate trials.
The comparable efficacy of the DPP-4 inhi-
bitors, along with other anti-diabetes treat-
ments (SGLT-2 inhibitors, GLP-1 agonists, and
the TZDs) in triple therapy have previously been
reported, and the NMA performed here has
further confirmed the expectation of no signif-
icant differences in key outcomes such as
change in HbA1c in a clinical trial setting when
comparing alogliptin with other DPP-4 inhibi-
tors [12–14, 36–40]. For example, the mean
change (%) in HbA1c for the grouped DPP-4
inhibitors compared to placebo was -0.64 and
-0.65 for fixed effects and random effects
models, respectively. Previous published
Fig. 12 Adverse events leading to treatment discontinua-
tion; main analysis set; ﬁxed and quasi-random (be-
tween-trial SD ﬁxed at 0.5) effects models. Forest plot of
pairwise comparisons between DPP-4 treatments (with
metformin ? SU) measured by log odds ratios
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meta-analyses of treatments for T2DM in triple
therapy (following failure with met-
formin ? SU) have reported similar results for
mean change in HbA1c: -0.68; [14] -0.62 [12],
and -0.69 [13]. The most recent NMA from Lee
et al. [15], which is the first study to estimate
and compare the effectiveness of all triple
therapy combinations that have been studied in
randomized trials, not limited to those that
included both metformin and SU, in terms of
HbA1c and the associated effect on body weight
and hypoglycemia, showed the mean change
(%) in HbA1c for the grouped DPP-4 inhibitors
compared to placebo was 0.56 which is a clini-
cally relevant reduction [15].
Strengths and Limitations
A strength of this study was the use of a deci-
sion-focused approach ensuring that the sys-
tematic search and the selected studies for the
NMA relate directly to the populations of
interest and the drug comparators of interest
that alogliptin is intended to displace in clinical
practice in the UK (i.e., other DPP-4 inhibitors).
The comparisons presented for alogliptin 25 mg
are for each comparator DPP-4 inhibitor at its
recommended daily dose to enhance the clini-
cal relevance of the results. The systematic
search and subsequent statistical analysis were
conducted according to a protocol specified in
advance, using transparent, reproducible
methods to identify evidence, perform data
abstraction, and conduct the analysis. Necessary
analytical deviations from the protocol (im-
possible to conduct specified random effect
models at the individual DPP-4 treatment level)
were handled in a transparent way: for example,
quasi-random effects models were created and
used as fully outlined in the methods section
and technical appendix.
The range of analyses performed for each
endpoint is another key strength. Specifically,
not only was alogliptin compared to each indi-
vidual DPP-4 comparator but these other com-
parators were individually compared against
each other. Visual comparisons from forest
plots across all pairwise comparisons were cru-
cial here to provide a context to assess the
alogliptin results. Even if all treatments are
equivalent, random chance (stochastic uncer-
tainty) will lead to non-identical estimates. By
showing all pairwise contrasts it is possible to
assess whether alogliptin comparisons have a
similar or different trend to the rest. The anal-
yses combining the other DPP-4 inhibitors into
one group to compare against alogliptin rests on
an assumption of comparable efficacy and
safety between the DPP-4inhibitors, which is
borne out by the results of the individual com-
parisons. Furthermore, this grouped analysis
was handled in a credible way—imposing vari-
ous different priors for the between-study stan-
dard deviation and assessing if this had any
effect at all on the results. The HbA1c non-in-
feriority probability analysis recognizes the
importance of clinically meaningful differences
in HbA1c and also demonstrates that there is a
very high probability that alogliptin is non-in-
ferior in efficacy to other DPP-4 inhibitors. Final
assessments concerning non-inferiority on an
endpoint were only made after looking across
the totality of results.
A further strength of the study was the
introduction of ‘‘partial pooling’’ techniques for
the purpose of addressing multiple testing
concerns. Having many statistical comparisons
performed across a range of sensitivity analysis
leads to an expectation of a number of statisti-
cally significant results for non-inferior treat-
ments: 1 in every 20 expected for independent
tests over non-inferior treatments at standard
0.05 P values (95% confidence/credible inter-
vals). Standard techniques to adjust for multiple
comparisons, such as Bonferroni, often increase
confidence intervals to unrealistic extents. One
method to deal with multiple testing concerns
in many instances is actually to make no direct
adjustment but simply show all comparisons
together and judge visually whether any obvi-
ous pattern involving a treatment emerges.
Hence, the one borderline (unadjusted for
multiple testing) statistically significant differ-
ence involving alogliptin against another DPP-4
inhibitor that arose in one sensitivity analysis
(Fig. 6 fixed effect sitagliptin comparison) is not
thought to be credible. A hierarchical ‘‘partial
pooling’’ approach to this fixed effect model was
implemented. This assumed that each
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individual DPP-4 treatment effect could be dif-
ferent from the rest but they all arose from the
same underlying normal distribution (whose
mean and variance priors were uninformative).
Such an assumption is plausible for treatments
within a class and for which there is no bio-
logical reason to expect a particular named
treatment to do better than any other before the
results are known—the conditions that arose in
the NMA. The implementation adopted was a
form of random effects model but importantly
it did not allow for between-trial heterogeneity
for the same treatment effect and so is equiva-
lent to the fixed effect model in this regard.
Confidence intervals are not increased with this
approach. Instead, estimates are pulled towards
the common effect—with a greater pull given to
the more extreme effects recorded with higher
uncertainty. As shown in Fig. 6, this shifted the
estimate to statistical insignificance.
There are inherent limitations with the
study. Firstly, the data for alogliptin is from a
post hoc subgroup analysis from the EXAMINE
trial, an event-driven cardiovascular outcomes
study, so patients enrolled were diagnosed with
type 2 diabetes and acute coronary syndrome,
and therefore could be considered ‘‘high risk’’.
In contrast the cardiovascular status of patients
in the comparator DPP-4 inhibitor studies is
limited with only one other study [32] reporting
data. As expected, there were fewer patients
with hypertension (51.2% vs. 83.6%) compared
to patients enrolled in the EXAMINE trial.
Similarly, baseline renal function was recorded
for patients in the EXAMINE trial (GFR\60 ml/
min/1.73 m2), and was comparable compared to
the two comparator DPP-4 inhibitor studies
(Lukashevich et al. [29.6% vs. 34.8%] [6] and
Owens et al. [5] [29.6% vs. 31.6%]) where this
was recorded. The study did not have as its
primary objective to evaluate the effects of alo-
gliptin on glycemic control [9] and so was not
powered to investigate the relative efficacy of
MET ? SU ? alogliptin vs. MET ? SU alone.
Patients were also permitted to have changes in
glycemic therapies according to local standard
of care including changes in the metformin, SU,
or existing dose. Thus background therapy at
baseline was intended to be indicative of
‘‘real-world’’ treatment, so doses of metformin
and type/dose of SU were neither standardized
nor controlled [10]. In addition, not all patients
who entered on metformin stayed on met-
formin and SU throughout the study follow-up,
although a large proportion did (84.9%) [10].
This is in contrast to the DPP-4 inhibitor com-
parator studies, whereby all patients were
intended to be on the maximum tolerated and
stable dose of MET ? SU. Further, whilst all
patients in the DPP-4 inhibitor comparator
studies were defined as having failed on
MET ? SU (i.e., baseline HbA1c [7% or 7.5%,
depending on study), there was no formal defi-
nition of failure in the EXAMINE study and the
inclusion criterion was HbA1c [6.5–11% [9]
(although the range for patients studied in the
post hoc subgroup was 4.9–11%). Overall, the
proportion of patients in the EXAMINE sub-
group who had HbA1c [7.5% and [7% was
64.9% and 81.3%, respectively; hence a large
proportion matched the patient population in
the other DPP-4 studies. So whilst the NMA
performed can only directly address the ques-
tion of the relative efficacy of alogliptin added
to MET ? SU compared to patients receiving
MET ? SU alone, on the basis of the similarity of
patient characteristics for EXAMINE versus
other studies it could be considered sufficient to
use this data and NMA as representative to
address the question of the relative efficacy of
alogliptin to MET ? SU in patients who have
failed on MET ? SU (i.e., have inadequate gly-
cemic control). This is relevant for HTA in
countries such as the UK where this is the
specific decision problem faced for new drug
therapies in triple therapy.
Despite the differences in study design and
patient inclusion criteria, the baseline charac-
teristics of patients in the metformin ? SU dual
therapy subgroup of EXAMINE were compara-
ble with patients in the other studies (e.g.,
baseline mean HbA1c of 8.15%, and mean
duration of diabetes of 8.5 years; see Table S3 in
the supplementary material). Hence, it is unli-
kely that these differences impact on the find-
ings of comparable efficacy and safety between
alogliptin and the other DPP-4 inhibitors in
triple therapy. Baseline HbA1c and duration of
T2DM are patient disease characteristics known
to potentially impact the efficacy of
Diabetes Ther (2017) 8:251–273 269
glucose-lowering treatments [41]. In a recent
meta-regression analysis by Esposito et al.
which aimed to predict the HbA1c response to
DPP-4 inhibitors including alogliptin, results
showed that a greater absolute reduction of
baseline HbA1c is seen in patients with higher
baseline HbA1c and lower fasting glucose level
[42]. This is consistent with previous reports for
other non-insulin glucose-lowering agents,
including SGLT-2 inhibitors [41, 43], sulfony-
lureas, metformin, and TZDs [44]. As the selec-
ted studies in the NMA had similar mean HbA1c
at baseline, the result of comparable efficacy in
the reduction of HbA1c from baseline between
alogliptin and the other DPP-4 inhibitors (sita-
gliptin, saxagliptin, linagliptin, and vildaglip-
tin) was as expected.
As a result of the limited availability of triple
therapy studies of a DPP-4 inhibitor in combi-
nation with metformin ? SU, studies were
restricted to 24-week follow-up only, whereas
dual therapy studies of a DPP-4 inhibitor in
combination with either metformin or SU, of
which there are many more, include studies
with a longer follow-up of 52 weeks. Despite
these limitations of the data, this post hoc
analysis does provide clinical evidence for the
triple use of alogliptin in combination with
metformin ? SU over a reasonable time period.
Because the NMA is a decision-focused
approach that concentrates on a comparison of
alternative DPP-4 inhibitors in triple therapy,
the studies selected are more homogeneous
than other broader NMAs in triple therapy that
have previously been reported [13, 14, 39], and
a relatively narrow network will reduce hetero-
geneity and noise that might be seen with larger
networks. The lack of studies preventing run-
ning NMA random effects models at the indi-
vidual DPP-4 treatment level has to be
acknowledged as a limitation. However, the
formulation of the quasi-random effects models
as a replacement, together with the strength of
results from all the combined analyses, provides
reassurance that such omission is not a major
concern.
Two features are worth pointing out con-
cerning these comparisons:
• The lower end definition of 0.3% has been
set as a clinically meaningful difference. The
upper end of 0.4% would actually show
alogliptin in a more favorable light (i.e.,
easier to achieve alogliptin non-inferiority).
Hence, in this context the estimates could be
considered conservative.
• Within random effect models as the
between-trial study contrast variance esti-
mates increase, then no matter what the true
difference is between the treatments, the
proportion of non-inferiority will fall (if the
true estimate is indeed high). This is a result
of higher between-trial variances dominat-
ing true differences.
The aim of performing a decision-focused
NMA was to potentially reduce between-study
heterogeneity and uncertainty as well as to
narrow credible intervals without any major
loss of precision—an approach that is suit-
able for HTA-based decision-making in the UK,
based on feedback received from UK HTA bod-
ies—the Scottish Medicines Consortium (SMC)
and All Wales Medicines Strategy Group
(AWMSG) [45, 46].
CONCLUSION
Triple therapy with a DPP-4 inhibitor in com-
bination with metformin and a sulfonylurea is
one of the current recommendations from NICE
if patients with T2DM have inadequate gly-
cemic control on dual therapy with metformin
and an SU [35]. This systematic review and
extensive analysis of DPP-4 treatments within
T2DM triple therapy settings (combined with
metformin ? SU) provides evidence of compa-
rability between alogliptin and other DPP-4
inhibitors in terms of key efficacy and safety
outcomes. In addition, this study has used a
number of techniques that may well be con-
sidered novel to traditional NMA methods—
quasi-random effects models (when random
effects models cannot be run) and ‘‘partial
pooling methods’’ (seeking to address multiple
testing issues) have been implemented in this
study that could be of use in future NMA
research. Local health service decision-makers
will need to consider the available evidence on
efficacy and safety, as well as cost and individ-
ual patient factors, when developing guidance
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and making formulary decisions about the use
of alogliptin. Alogliptin has the lowest acquisi-
tion cost of all the DPP-4 inhibitors used in UK
clinical practice [47]; hence, it could be con-
sidered to have relative cost-effectiveness based
on the finding of comparable efficacy and safety
from this NMA. The current NMA should help
local decision-makers have a clearer under-
standing of the drug’s place in therapy. Further
RCT evidence from additional clinical studies
investigating alogliptin added to metformin
plus a sulfonylurea and further active com-
parator studies comparing alogliptin with other
DPP-4 inhibitors would be useful to further
strengthen the evidence base for alogliptin in
triple therapy.
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